Literature DB >> 7679413

Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patients.

A Valli1, A Sette, L Kappos, C Oseroff, J Sidney, G Miescher, M Hochberger, E D Albert, L Adorini.   

Abstract

Multiple sclerosis (MS) is an autoimmune disease in which myelin proteins have been implicated as autoantigens recognized by pathogenic autoreactive T cells. To study the relationship between human myelin basic protein (hMBP) and HLA alleles associated to MS susceptibility, such as DRB1*1501, the binding of synthetic peptides spanning the entire hMBP sequence to 10 purified HLA-DR molecules was determined. All the hMBP peptides tested showed binding affinity for at least one of the DR molecules analyzed, but three hMBP peptides, included in sequences 13-32, 84-103, and 144-163 were found capable of binding to three or more DR molecules. The hMBP peptide 84-103 was the most degenerate in binding, in that it bound to 9 out of 10 DR molecules tested. Interestingly, it bound with highest affinity to DRB1*1501 molecules. To correlate the binding pattern of hMBP peptides to HLA class II molecules with their recognition by T cells, 61 hMBP-specific T cell lines (TCL) were established from the peripheral blood of 20 MS patients, who were homozygous, heterozygous, or negative for DRB1*1501. Analysis of hMBP epitopes recognized by these TCL and their HLA restriction demonstrated a very good correlation between binding data and T cell proliferation to hMBP peptides. Although virtually all hMBP peptides tested could be recognized by at least one TCL from MS patients, three immunodominant T cell epitopes were apparent among the TCL examined, corresponding exactly to the hMBP peptides capable of binding to several DR molecules. No major difference could be detected in the recognition of immunodominant hMBP peptides by TCL from DRB1*1501 positive or negative MS patients. These results have implications for the role of hMBP as relevant autoantigen, and of DRB1*1501 as susceptibility allele in MS.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7679413      PMCID: PMC287995          DOI: 10.1172/JCI116242

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  58 in total

1.  Immunogenetic profile of multiple sclerosis in Mexicans.

Authors:  C Gorodezky; R Najera; B E Rangel; L E Castro; J Flores; G Velázquez; J Granados; J Sotelo
Journal:  Hum Immunol       Date:  1986-08       Impact factor: 2.850

2.  A population-based study of multiple sclerosis in twins.

Authors:  G C Ebers; D E Bulman; A D Sadovnick; D W Paty; S Warren; W Hader; T J Murray; T P Seland; P Duquette; T Grey
Journal:  N Engl J Med       Date:  1986-12-25       Impact factor: 91.245

3.  Adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice after in vitro activation of lymph node cells by myelin basic protein: requirement for Lyt 1+ 2- T lymphocytes.

Authors:  C B Pettinelli; D E McFarlin
Journal:  J Immunol       Date:  1981-10       Impact factor: 5.422

4.  The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis.

Authors:  A Ben-Nun; H Wekerle; I R Cohen
Journal:  Eur J Immunol       Date:  1981-03       Impact factor: 5.532

5.  Distinct forms of both alpha and beta subunits are present in the human Ia molecular pool.

Authors:  R S Accolla; N Gross; S Carrel; G Corte
Journal:  Proc Natl Acad Sci U S A       Date:  1981-07       Impact factor: 11.205

6.  T-cell clones specific for myelin basic protein induce chronic relapsing paralysis and demyelination.

Authors:  S Zamvil; P Nelson; J Trotter; D Mitchell; R Knobler; R Fritz; L Steinman
Journal:  Nature       Date:  1985 Sep 26-Oct 2       Impact factor: 49.962

7.  Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).

Authors:  J F Kurtzke
Journal:  Neurology       Date:  1983-11       Impact factor: 9.910

8.  Detection of a novel human class II HLA antigen.

Authors:  A J Watson; R DeMars; I S Trowbridge; F H Bach
Journal:  Nature       Date:  1983 Jul 28-Aug 3       Impact factor: 49.962

9.  HLA and Japanese MS.

Authors:  S Naito; Y Kuroiwa; T Itoyama; T Tsubaki; A Horikawa; T Sasazuki; S Noguchi; S Ohtsuki; H Tokuomi; T Miyatake; N Takahata; S Kawanami
Journal:  Tissue Antigens       Date:  1978-07

10.  T-cell epitope of the autoantigen myelin basic protein that induces encephalomyelitis.

Authors:  S S Zamvil; D J Mitchell; A C Moore; K Kitamura; L Steinman; J B Rothbard
Journal:  Nature       Date:  1986 Nov 20-26       Impact factor: 49.962

View more
  52 in total

1.  Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules.

Authors:  G Zeng; C E Touloukian; X Wang; N P Restifo; S A Rosenberg; R F Wang
Journal:  J Immunol       Date:  2000-07-15       Impact factor: 5.422

2.  Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection.

Authors:  H M Diepolder; J T Gerlach; R Zachoval; R M Hoffmann; M C Jung; E A Wierenga; S Scholz; T Santantonio; M Houghton; S Southwood; A Sette; G R Pape
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

3.  Recognition of the immunodominant myelin basic protein peptide by autoantibodies and HLA-DR2-restricted T cell clones from multiple sclerosis patients. Identity of key contact residues in the B-cell and T-cell epitopes.

Authors:  K W Wucherpfennig; I Catz; S Hausmann; J L Strominger; L Steinman; K G Warren
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

Review 4.  Immunopathogenesis of multiple sclerosis: MBP and beyond.

Authors:  E Meinl; R Hohlfeld
Journal:  Clin Exp Immunol       Date:  2002-06       Impact factor: 4.330

Review 5.  Unusual features of self-peptide/MHC binding by autoimmune T cell receptors.

Authors:  Melissa J Nicholson; Michael Hahn; Kai W Wucherpfennig
Journal:  Immunity       Date:  2005-10       Impact factor: 31.745

6.  Myelin-reactive type B T cells and T cells specific for low-affinity MHC-binding myelin peptides escape tolerance in HLA-DR transgenic mice.

Authors:  Kazuyuki Kawamura; Katherine A McLaughlin; Robert Weissert; Thomas G Forsthuber
Journal:  J Immunol       Date:  2008-09-01       Impact factor: 5.422

7.  Small molecule inhibitor of antigen binding and presentation by HLA-DR2b as a therapeutic strategy for the treatment of multiple sclerosis.

Authors:  Niannian Ji; Animesh Somanaboeina; Aakanksha Dixit; Kazuyuki Kawamura; Neil J Hayward; Christopher Self; Gary L Olson; Thomas G Forsthuber
Journal:  J Immunol       Date:  2013-10-11       Impact factor: 5.422

8.  Naturally presented peptides on major histocompatibility complex I and II molecules eluted from central nervous system of multiple sclerosis patients.

Authors:  Nicolas Fissolo; Sabrina Haag; Katrien L de Graaf; Oliver Drews; Stefan Stevanovic; Hans Georg Rammensee; Robert Weissert
Journal:  Mol Cell Proteomics       Date:  2009-06-16       Impact factor: 5.911

9.  Differences in susceptibility of MBP charge isomers to digestion by stromelysin-1 (MMP-3) and release of an immunodominant epitope.

Authors:  Cheryl A D'Souza; Mario A Moscarello
Journal:  Neurochem Res       Date:  2006-07-27       Impact factor: 3.996

10.  Fine specificity of the antibody response to myelin basic protein in the central nervous system in multiple sclerosis: the minimal B-cell epitope and a model of its features.

Authors:  K G Warren; I Catz; L Steinman
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.